Since making the split from AbbVie (Nasdaq:ABBV), Abbott Labs (NYSE:ABT) has had something of a mixed debut. The stock has not only lagged AbbVie to a meaningful degree this year, but also other med-tech stocks like Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ). While some of this can be tied to concerns about the infant nutrition business, the fact remains that the new Abbott isn't as high-growth or high-margin as some investors want to believe, and management has their work cut out to improve performance. I do like the company's recent M&A moves to bulk up the device business, but this doesn't look like a particularly cheap stock today.
Decent Q2 Earnings With Improving Margins
One of the big items on the Abbott Labs to-do list is to drive better margins, and the company certainly made some progress this quarter. Even so, lower-than-expected growth in emerging markets is likely to linger as a concern, and the company's device business is looking quite soft at the moment.
Overall revenue rose more than 2% as reported, or about 4% on a constant currency basis, missing estimates slightly. Nutrition led the way in terms of growth (up more than 8% cc) and absolute dollars (31% of the total), but still missed the sell-side target by about 2%. OUS growth was a robust 17%, but slowdowns in emerging markets are a bit of a concern for the industry. 

SEE: Strategies For Quarterly Earnings Season

Abbott's other business were more mediocre. Diagnostics revenue was up almost 8%, but device revenue was virtually flat and branded generics (“Established Pharmaceuticals) revenue was down 2% as reported and barely up in constant currency terms.
Margins were more positive. Gross margin declined almost a point from the year-ago level, but were still about a half-point higher than expected. Likewise, adjusted operating income was only up about 4%, but the operating margin was about 30bp better than expected and the SG&A/revenue ratio declined 70bp from last year.
No Joy In Devices, And Probably Not Much On The Way Immediately
Given the earnings we've seen so far (and analyst expectations for those who haven't reported), Abbott's weak results in devices aren't a big surprise. Even so, barely positive revenue in vascular probably won't improve immediately, and the company is looking at serious, sustained competitive pressures from the likes of Medtronic and Boston Scientific (NYSE: BSX) in drug-eluting stents, Medtronic, BSX, JNJ, Covidien (NYSE:COV), and Bard (NYSE:BCR) in peripheral, and many of the above in structural heart.
Diabetes was more mixed. The slight decline in revenue was unimpressive on its own, but quite good compared to the significant decline at JNJ and the declines expected at Roche (Nasdaq:RHHBY) as Medicare changes its reimbursement policies for glucose testing.
Building A Better Business Will Take Time
Abbott has a very good nutrition business which, along with Mead Johnson (NYSE:MJN) dominates the U.S. market for infant and adult nutrition. The company is also looking to gain share in China, a huge market that is likely to account for more than half of global growth in the next five years. While China is already cracking down on the high price of formula in the country (and Abbott has already responded with a price cut), and companies like Mead Johnson, Nestle (Nasdaq:NSRGY), and Danone (Nasdaq:DANOY) are serious competitors, I like Abbott's chances for share growth, not to mention the under-appreciated potential of adult nutrition (Ensure), which only recently launched in China.
There's work to do elsewhere, though. The company recently made two promising acquisitions in the peripheral vascular and vision care spaces, but I think the company could use some additional growth-oriented business platforms. Along similar lines, Abbott could really stand to beef up its automation capabilities in the diagnostics space. It's also important for the company to improve margins, as the overall margin picture isn't all that great relative to its peer group.
The Bottom Line
I'm not as enamored with Abbott as some investors, but that's largely tied to what I see as incomplete platforms in devices and diagnostics that are likely going to require further M&A and/or management attention. The nutrition business will patch over a lot of holes, though, and the EPD business should be a good business on balance.
Even with an expectation of mid-teens free cash flow growth over the next decade, Abbott shares don't look like a particular bargain. There's certainly upside if Abbott's emerging market nutrition business grows faster than expected and/or if the device business improves its growth and/or margins faster than I expect. As is, though, I think $36 to $37 is a pretty fair price for the stock.

Disclosure - As of this writing, the author owns shares of Roche.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center